Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines

Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines

US Patent 8394385 · Granted Mar 12, 2013

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding fil2022
PR13.5 promoter for robust T-cell and antibody responses2021
Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogen2020
Poxviral vectors for low antibody response after a first priming immunization2018
Pr13.5 promoter for robust T-cell and antibody responses2017
Recombinant modified vaccinia virus Ankara influenza vaccine2015
Replication deficient recombinant viruses expressing antigens regulated by trans2015
Replication deficient recombinant viruses expressing antigens regulated by trans2015
Replication deficient recombinant viruses expressing antigens regulated by trans2015
Modulation of immune responses by the poxviral K4 protein2014
Vaccinia virus mutants containing the major genomic deletions of MVA2014
Replication deficient recombinant viruses expressing antigens regulated by trans2013